CN106102743A - 用于预防或治疗共济失调病症的哒嗪衍生物 - Google Patents

用于预防或治疗共济失调病症的哒嗪衍生物 Download PDF

Info

Publication number
CN106102743A
CN106102743A CN201580012352.1A CN201580012352A CN106102743A CN 106102743 A CN106102743 A CN 106102743A CN 201580012352 A CN201580012352 A CN 201580012352A CN 106102743 A CN106102743 A CN 106102743A
Authority
CN
China
Prior art keywords
ethyl
hydroxypyridazin
hydroxyl
trifluoromethyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580012352.1A
Other languages
English (en)
Chinese (zh)
Inventor
S.阿尔蒙德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50554599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106102743(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CN106102743A publication Critical patent/CN106102743A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580012352.1A 2014-03-06 2015-03-06 用于预防或治疗共济失调病症的哒嗪衍生物 Pending CN106102743A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1403944.0A GB201403944D0 (en) 2014-03-06 2014-03-06 New use
GB1403944.0 2014-03-06
PCT/GB2015/050654 WO2015132608A1 (en) 2014-03-06 2015-03-06 Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder

Publications (1)

Publication Number Publication Date
CN106102743A true CN106102743A (zh) 2016-11-09

Family

ID=50554599

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580012352.1A Pending CN106102743A (zh) 2014-03-06 2015-03-06 用于预防或治疗共济失调病症的哒嗪衍生物

Country Status (32)

Country Link
US (1) US20170014407A1 (https=)
EP (1) EP3113778B1 (https=)
JP (1) JP6510549B2 (https=)
KR (1) KR20160126081A (https=)
CN (1) CN106102743A (https=)
AU (1) AU2015225954B2 (https=)
CA (1) CA2940342A1 (https=)
CL (1) CL2016002151A1 (https=)
CY (1) CY1120573T1 (https=)
DK (1) DK3113778T3 (https=)
EA (1) EA036438B1 (https=)
ES (1) ES2676905T3 (https=)
GB (1) GB201403944D0 (https=)
GE (2) GEAP201914284A (https=)
HR (1) HRP20181082T1 (https=)
IL (1) IL247435A0 (https=)
LT (1) LT3113778T (https=)
MA (1) MA39315A1 (https=)
MX (1) MX2016010524A (https=)
MY (1) MY202127A (https=)
PH (1) PH12016501751A1 (https=)
PL (1) PL3113778T3 (https=)
PT (1) PT3113778T (https=)
RS (1) RS57594B1 (https=)
SG (1) SG11201607106YA (https=)
SI (1) SI3113778T1 (https=)
SM (1) SMT201800367T1 (https=)
TR (1) TR201809537T4 (https=)
TW (1) TW201534591A (https=)
UA (1) UA123352C2 (https=)
WO (1) WO2015132608A1 (https=)
ZA (1) ZA201604611B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112569217A (zh) * 2019-09-30 2021-03-30 厦门大学 戊酸衍生物在治疗遗传性小脑共济失调中的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
PT3137456T (pt) 2014-04-29 2021-08-06 Fmc Corp Herbicidas de piridazinona
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
US11213030B2 (en) 2017-06-30 2022-01-04 Fmc Corporation 4-(3,4-dihydronaphth-1-yl or 2H-chromen-4-yl)-5-hydroxy-2H-pyradizin-3-ones as herbicides
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
PE20232048A1 (es) 2021-03-01 2023-12-27 Neurocrine Biosciences Inc Uso de luvadaxistat para el tratamiento de deterioro cognitivo

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047558A2 (en) * 2001-12-03 2003-06-12 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
US20130052281A1 (en) * 2011-08-22 2013-02-28 Takeda Pharmaceutical Company Limited Novel compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2262322T3 (es) * 1998-06-10 2006-11-16 Meiji Seika Kaisha, Ltd. Tratamiento de la degenaracion espinocereberal y comoposiciones utiles para el tratamiento de degeneracion espinocerebelar.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047558A2 (en) * 2001-12-03 2003-06-12 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
US20130052281A1 (en) * 2011-08-22 2013-02-28 Takeda Pharmaceutical Company Limited Novel compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112569217A (zh) * 2019-09-30 2021-03-30 厦门大学 戊酸衍生物在治疗遗传性小脑共济失调中的应用
CN112569217B (zh) * 2019-09-30 2022-04-22 厦门大学 戊酸衍生物在治疗遗传性小脑共济失调中的应用

Also Published As

Publication number Publication date
GB201403944D0 (en) 2014-04-23
ES2676905T3 (es) 2018-07-26
SG11201607106YA (en) 2016-09-29
EA036438B1 (ru) 2020-11-11
UA123352C2 (uk) 2021-03-24
PL3113778T3 (pl) 2018-11-30
GEP20196984B (en) 2019-06-25
SMT201800367T1 (it) 2018-09-13
JP6510549B2 (ja) 2019-05-08
RS57594B1 (sr) 2018-11-30
TW201534591A (zh) 2015-09-16
PT3113778T (pt) 2018-07-11
EA201691566A1 (ru) 2016-12-30
PH12016501751A1 (en) 2017-02-06
US20170014407A1 (en) 2017-01-19
CA2940342A1 (en) 2015-09-11
AU2015225954A1 (en) 2016-07-07
EP3113778A1 (en) 2017-01-11
IL247435A0 (en) 2016-11-30
LT3113778T (lt) 2018-08-27
EP3113778B1 (en) 2018-06-06
MA39315A1 (fr) 2017-09-29
CL2016002151A1 (es) 2016-12-30
KR20160126081A (ko) 2016-11-01
DK3113778T3 (en) 2018-07-30
WO2015132608A1 (en) 2015-09-11
HRP20181082T1 (hr) 2018-09-07
TR201809537T4 (tr) 2018-07-23
JP2017507156A (ja) 2017-03-16
AU2015225954B2 (en) 2020-06-18
SI3113778T1 (en) 2018-08-31
ZA201604611B (en) 2017-09-27
CY1120573T1 (el) 2019-07-10
GEAP201914284A (en) 2019-02-25
MY202127A (en) 2024-04-05
MX2016010524A (es) 2016-10-31

Similar Documents

Publication Publication Date Title
EP3113778B1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
Carroll Monoamine precursors in the treatment of depression
JP5605659B2 (ja) 細胞保護剤
JP6668045B2 (ja) ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
EP3615028A1 (en) Pimavanserin for treating impulse control disorder
EA014576B1 (ru) Комбинированные препараты, содержащие бифепрунокс и l-допу
JP6629464B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種類の組合せ
JP2024153742A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物
Júnior et al. Effects of constant intravenous infusion of detomidine alone or combined with butorphanol or methadone for standing sedation in horses: a randomized clinical trial
US20080318926A1 (en) Methods of Treating Mood Disorders Using Pyridyloxymethyl and Benzisoxazole Azabicyclic Derivatives
WO2022079304A1 (en) Compositions and uses thereof
HK1230925A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
EP4208161A1 (en) Compositions and uses thereof
JP2019528261A (ja) ヒスタミン−３受容体インバースアゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種組合せ
CN107648235B (zh) 普纳替尼在制备治疗缺血/再灌注损伤药物中的应用
Evans THE CHALLENGE
Klisko Targeting Muscarinic Receptor Subtypes as a Therapeutic Approach in Dystonia and Parkinson's Disease
Rizek et al. Management of Advanced Parkinson’s Disease
HK1262796B (en) Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors
HK1262796A1 (en) Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors
TW200524920A (en) Treatment of circadian rhythm disorders with NPY Y5 receptor antagonist
UA9407U (en) Method for treating diabetic retinopathy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1230925

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20161109

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1230925

Country of ref document: HK